MAZE

#2181
Maze Therapeutics, Inc. - Common Stock
27.4 4 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
27.44
27.44
Jahresspanne
22.71
53.65
Tagesänderung
-4.06%
Monatliche Änderung
+2.62%
6 month change
-38.34%
Jahresänderung
-39.06%
Vorheriger Schlusskurs
28.6 0
Open
27.4 4
Tief
27.4 4
Hoch
27.4 4
Volumen
67
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, 13 Aug 2026
Maze Therapeutics, Inc. current report, 13 August 2026
8-K
Current report, Q3 FY2026
Maze Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Maze Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Maze Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Maze Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Maze Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Maze Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Maze Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Maze Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Maze Therapeutics, Inc. current report, Q1 FY2026
8-K

Maze Therapeutics, Inc. current report, 13 August 2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Maze Therapeutics, Inc. on August 17, 2026, covering events that occurred on August 13, 2026. The filing primarily addresses corporate governance changes, specifically the appointment of new directors and the restructuring of director classes to maintain staggered terms.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.

Material Changes

  • New Director Appointments: The Board appointed Paula A. Johnson, M.D., M.P.H., as a Class III director and Sophie Kornowski, Pharm.D., as a Class I director, effective August 13, 2026.
  • Committee Assignments: Dr. Johnson was appointed to the Nominating and Corporate Governance Committee. Dr. Kornowski was appointed to the Audit and Compensation Committees.
  • Director Class Restructuring: To balance the board classes, Nancy C. Andrews, M.D., Ph.D., was reclassified from Class III to Class II, and Hervé Hoppenot was reclassified from Class II to Class III.

Compensation and Governance Details

In connection with their appointments, Dr. Johnson and Dr. Kornowski received compensation under the Company's non-employee director policy:

  • Cash Retainer: A pro rata portion of the $40,000 annual cash retainer for the remainder of the year, plus applicable committee retainers.
  • Equity Award: Each director received an option to purchase 36,000 shares of common stock. These options vest monthly (1/36th per month) subject to continued service.

The filing includes a press release (Exhibit 99.1) regarding these appointments but explicitly states that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Verify the specific vesting schedule and exercise price of the 36,000 share options granted to the new directors.
  • Confirm the updated composition of the Board of Directors and committee memberships following the class reassignments.
  • Review the full text of the press release (Exhibit 99.1) for any additional strategic context regarding the new appointments.
  • Check subsequent filings for any financial impact related to the new director compensation, as this 8-K does not quantify the total equity expense.